Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





UV-C Light Kills SARS-CoV-2 Virus Within Seconds of Exposure in Lab Study

By HospiMedica International staff writers
Posted on 23 Jun 2020
A UV-C lighting technology developed by Signify (Eindhoven, The Netherlands) has proven to be effective in inactivating the SARS-CoV-2 virus in research studies.

In tests conducted by Signify, together with the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University (Boston, MA, USA), the SARS-CoV-2 virus could no longer be detected after seconds of exposure to UV-C light sources. More...
During their research, the scientists treated inoculated material with different doses of UV-C radiation coming from a Signify light source and assessed the inactivation capacity under various conditions. The team applied a dose of 5mJ/cm2, resulting in a reduction of the SARS-CoV-2 virus of 99% in six seconds. Based on the data, it was determined that a dose of 22mJ/cm2 will result in a reduction of 99.9999% in 25 seconds.

I’m very happy about the fruitful cooperation with Boston University in the fight against the coronavirus. Boston University has validated the effectiveness of our light sources as a preventive measure for companies and institutions as they seek ways to provide virus-free environments,” said Eric Rondolat, CEO of Signify. “Given the potential of the technology to aid the fight against the coronavirus, Signify will not keep the technology for its exclusive use but make it available to other lighting companies. To service the growing need for disinfection we will increase our production capacity multifold in the coming months.”

“Our test results show that above a specific dose of UV-C radiation, viruses were completely inactivated: in a matter of seconds we could no longer detect any virus,” said Dr. Anthony Griffiths, Associate Professor of Microbiology at Boston University School of Medicine. “We’re very excited about these findings and hope that this will accelerate the development of products that can help limit the spread of COVID-19.”

Related Links:
Signify
Boston University



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.